Clinical Trial Update: A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

View source ↗

Summary

A clinical trial update from Amryt Pharma about a study to assess the incidence of skin cancers in patients with epidermolysis bullosa receiving Filsuvez.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epidermolysis Bullosa
• Epidermolysis Bullosa Dystrophic
• Epidermolysis Bullosa Junctional

Drugs mentioned

• Filsuvez (beremagene geperpavec)

Snippet

Sponsor: Amryt Pharma | Conditions: Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional | Status: RECRUITING